A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery

Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case,...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Yiqi, Ding, Zheng, Deng, Xianzhao, Guo, Bomin, Kang, Jie, Wu, Bo, Fan, Youben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188788/
https://www.ncbi.nlm.nih.gov/pubmed/32390940
http://dx.doi.org/10.3389/fendo.2020.00207
Descripción
Sumario:Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case, the (125)I seed implantation and vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor apatinib were co-applied to treat a 49-year-old woman with anaplastic thyroid cancer. After the patient began apatinib administration and underwent (125)I seed implantation twice, the tumor size shrank successfully. After a follow-up of 13 months since the initial diagnosis of anaplastic thyroid cancer, the patient survived with a stable disease pathology. In conclusion, this study supports (125)I seed implantation and apatinib as effective therapeutic alternatives for inoperable anaplastic thyroid cancer patients.

Ejemplares similares